Comparison of Sorafenib and DEB-TACE in patients wth hepatocellular carcinoma refractory to conventional TACE.

Comparison of Sorafenib and DEB-TACE in patients wth hepatocellular carcinoma refractory to conventional TACE. - The investigation for the therapy of hepatocellular carcinoma refractory to conventional TACE.

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014999

Enrollment

100

Registered

2014-09-01

Start date

2014-09-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Patients with HCC. 2)Patients whose TMN stage of HCC is II, III or IVa. 3)Patiets that written agreement of participation for this study was obtained. 4)Patients with HCC refractory to conventional TACE. 5)Patients whose Child-Pugh is A.

Exclusion criteria

Exclusion criteria: 1)Patiets that written agreement of participation for this study was not obtained. 2)Patients whose HCC with invasion of stem of portal vein. 3)Patients with uncontrollable ascites. 4)Patients whose TMN stage of HCC is IVb. 5)Patients whose Child-Pugh is B or C. 6)Pregnant patiients. 7)Patients with iodine hypersensitivity. 8)Patients who were estimated that study entry is inappropriate by the responsible physician.

Design outcomes

Primary

Measure	Time frame
overall survival rate	—

Secondary

Measure	Time frame
progression-free survival response rate	—

Countries

Japan

Contacts

Public Contacthironori Ochi

Matsuyama Red Cross Hospital Center for liver-Billiary-Pancreatic Diseases

hironori19810211@matsuyama.jrc.or.jp089-924-1111

Outcome results